MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1136/jmg-2023-109445

Медицинская библиотека · Journal of medical genetics · 2024

Head-to-head trial of pegunigalsidase alfa versus agalsidase beta in patients with Fabry disease and deteriorating renal function: results from the 2-year randomised phase III BALANCE study.

Wallace Eric L, Goker-Alpan Ozlem, Wilcox William R, Holida Myrl, Bernat John, Longo Nicola, Linhart Aleš, Hughes Derralynn A, Hopkin Robert J, Tøndel Camilla, Langeveld Mirjam, Giraldo Pilar, Pisani Antonio, Germain Dominique Paul, Mehta Ankit, Deegan Patrick B, Molnar Maria Judit, Ortiz Damara, Jovanovic Ana, Muriello Michael, Barshop Bruce A, Kimonis Virginia, Vujkovac Bojan, Nowak Albina, Geberhiwot Tarekegn, Kantola Ilkka, Knoll Jasmine, Waldek Stephen, Nedd Khan, Karaa Amel, Brill-Almon Einat, Alon Sari, Chertkoff Raul, Rocco Rossana, Sakov Anat, Warnock David G

СтатьяРандомизированное исследованиеКлиническое исследование III фазыМногоцентровое исследованиеПоддержка исследования: вне правительства СШАПеревод пока не подготовлен

Аннотация

BACKGROUND

Pegunigalsidase alfa is a PEGylated α-galactosidase A enzyme replacement therapy. BALANCE (NCT02795676) assessed non-inferiority of pegunigalsidase alfa versus agalsidase beta in adults with Fabry disease with an annualised estimated glomerular filtration rate (eGFR) slope more negative than -2 mL/min/1.73 m2/year who had received agalsidase beta for ≥1 year.

METHODS

Patients were randomly assigned 2:1 to receive 1 mg/kg pegunigalsidase alfa or agalsidase beta every 2 weeks for 2 years. The primary efficacy analysis assessed non-inferiority based on median annualised eGFR slope differences between treatment arms.

RESULTS

Seventy-seven patients received either pegunigalsidase alfa (n=52) or agalsidase beta (n=25). At baseline, mean (range) age was 44 (18-60) years, 47 (61%) patients were male, median eGFR was 74.5 mL/min/1.73 m2 and median (range) eGFR slope was -7.3 (-30.5, 6.3) mL/min/1.73 m2/year. At 2 years, the difference between median eGFR slopes was -0.36 mL/min/1.73 m2/year, meeting the prespecified non-inferiority margin. Minimal changes were observed in lyso-Gb3 concentrations in both treatment arms at 2 years. Proportions of patients experiencing treatment-related adverse events and mild or moderate infusion-related reactions were similar in both groups, yet exposure-adjusted rates were 3.6-fold and 7.8-fold higher, respectively, with agalsidase beta than pegunigalsidase alfa. At the end of the study, neutralising antibodies were detected in 7 out of 47 (15%) pegunigalsidase alfa-treated patients and 6 out of 23 (26%) agalsidase beta-treated patients. There were no deaths.

CONCLUSIONS

Based on rate of eGFR decline over 2 years, pegunigalsidase alfa was non-inferior to agalsidase beta. Pegunigalsidase alfa had lower rates of treatment-emergent adverse events and mild or moderate infusion-related reactions.

TRIAL REGISTRATION NUMBER: NCT02795676.

Для цитирования: Wallace Eric L, Goker-Alpan Ozlem, Wilcox William R, Holida Myrl, Bernat John, Longo Nicola, Linhart Aleš, Hughes Derralynn A, Hopkin Robert J, Tøndel Camilla, Langeveld Mirjam, Giraldo Pilar, Pisani Antonio, Germain Dominique Paul, Mehta Ankit, Deegan Patrick B, Molnar Maria Judit, Ortiz Damara, Jovanovic Ana, Muriello Michael, Barshop Bruce A, Kimonis Virginia, Vujkovac Bojan, Nowak Albina, Geberhiwot Tarekegn, Kantola Ilkka, Knoll Jasmine, Waldek Stephen, Nedd Khan, Karaa Amel, Brill-Almon Einat, Alon Sari, Chertkoff Raul, Rocco Rossana, Sakov Anat, Warnock David G. Head-to-head trial of pegunigalsidase alfa versus agalsidase beta in patients with Fabry disease and deteriorating renal function: results from the 2-year randomised phase III BALANCE study.. Journal of medical genetics. 2024. DOI: 10.1136/jmg-2023-109445.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.